Novo Paints Murky Cardio Picture for Semaglutide Franchise
“According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower cardiovascular death and nonfatal stroke.”
Novo Paints Murky Cardio Picture for Semaglutide Franchise
“According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower cardiovascular death and nonfatal stroke.”